drugset / Trial / NCT02942095
Study of Ixazomib and Erlotinib in Solid Tumors
Phase 1
Completed
9 enrolled
M.D. Anderson Cancer Center
Millennium: The Takeda Oncology Company · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of ixazomib and erlotinib that can be given to patients with advanced solid tumors. The safety of these drugs will also be studied. This is an investigational study. Erlotinib is FDA approved and commercially available to treat non-small cell lung cancer, but its use in advanced solid cancer is considered investigational. Ixazomib is FDA approved. The study doctor can explain how the study drugs are designed to work. Up to 36 patients will take part in this study. All will be enrolled at MD Anderson.
Timeline
- Start
- 2017-03-06
- Primary completion
- 2022-12-07
- Completion
- 2022-12-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Ixazomib | Unknown | 3 mg | Oral |